tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PRLD Stock Latest News

Prelude Therapeutics files to sell 6.25M shares of common stock for holders
The FlyPrelude Therapeutics files to sell 6.25M shares of common stock for holders
19d ago
PRLD
Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs
PremiumThe Fly
Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs
23d ago
PRLD
Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges
PremiumCompany Announcements
Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges
2M ago
PRLD
Prelude Therapeutics Advances Pipeline and Strengthens Financials
PremiumCompany Announcements
Prelude Therapeutics Advances Pipeline and Strengthens Financials
2M ago
PRLD
Prelude Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Prelude Therapeutics Reports Q3 2025 Financial Results
2M ago
8K
PRLD
Prelude Therapeutics reports Q3 EPS (26c) vs. (43c) last year
PremiumThe FlyPrelude Therapeutics reports Q3 EPS (26c) vs. (43c) last year
2M ago
PRLD
Prelude Therapeutics sees cash runway into 2027
Premium
The Fly
Prelude Therapeutics sees cash runway into 2027
2M ago
PRLD
Is PRLD a Buy, Before Earnings?
Premium
Pre-Earnings
Is PRLD a Buy, Before Earnings?
2M ago
PRLD
Prelude Therapeutics Signs Option Agreement with Incyte
PremiumCompany Announcements
Prelude Therapeutics Signs Option Agreement with Incyte
2M ago
8K
PRLD
Why Is Prelude Therapeutics Stock (PRLD) Down 45% Today?
PremiumMarket News
Why Is Prelude Therapeutics Stock (PRLD) Down 45% Today?
2M ago
INCY
PRLD
Prelude Therapeutics announces exclusive option agreement with Incyte
PremiumThe Fly
Prelude Therapeutics announces exclusive option agreement with Incyte
2M ago
INCY
PRLD
Prelude to prioritize JAK2V617F JH2 inhibitor, KAT6A selective degrader programs
PremiumThe Fly
Prelude to prioritize JAK2V617F JH2 inhibitor, KAT6A selective degrader programs
2M ago
INCY
PRLD
Prelude Therapeutics pauses development of SMARCA2 degrader program
PremiumThe FlyPrelude Therapeutics pauses development of SMARCA2 degrader program
2M ago
PRLD
Prelude Therapeutics sees cash runway into 2027
Premium
The Fly
Prelude Therapeutics sees cash runway into 2027
2M ago
PRLD
Prelude Therapeutics CMO Jane Huang departs
Premium
The Fly
Prelude Therapeutics CMO Jane Huang departs
2M ago
PRLD
Prelude Therapeutics announces publication of abstracts for ASH meeting
PremiumThe Fly
Prelude Therapeutics announces publication of abstracts for ASH meeting
2M ago
PRLD
Prelude Therapeutics Advances with PRT7732 in Targeted Cancer Therapy
PremiumCompany Announcements
Prelude Therapeutics Advances with PRT7732 in Targeted Cancer Therapy
2M ago
PRLD
Prelude Therapeutics Appoints Katina Dorton to Board
PremiumCompany Announcements
Prelude Therapeutics Appoints Katina Dorton to Board
2M ago
8K
PRLD
Prelude Therapeutics appoints Katina Dorton to board of directors
PremiumThe Fly
Prelude Therapeutics appoints Katina Dorton to board of directors
2M ago
PRLD
Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating
PremiumRatingsPrelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating
3M ago
PRLD
Prelude Therapeutics Regains Nasdaq Compliance
Premium
Company Announcements
Prelude Therapeutics Regains Nasdaq Compliance
3M ago
8K
PRLD
Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP
Premium
The Fly
Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP
4M ago
PRLD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >